Navitoclax-piperazine is primarily utilized in the field of oncology, particularly in cancer research and treatment. It functions as a potent inhibitor of BCL-2 family proteins, which play a crucial role in regulating apoptosis, or programmed cell death, in cancer cells. By targeting these proteins, it helps to induce apoptosis in cancer cells that are otherwise resistant to conventional therapies. This makes it a valuable compound in the development of treatments for various types of cancers, including hematologic malignancies and solid tumors. Additionally, it is often used in preclinical studies to understand the mechanisms of drug resistance and to explore combination therapies that enhance the efficacy of existing cancer treatments.